Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1112 results found since Jan 2013.
Pharmacogenetic analysis of inter-ethnic variability in the uptake transporter SLCO1B1 gene in Colombian, Mozambican, and Portuguese populations
Statin-induced myopathy is reported to be associated with the solute carrier organic anion transporter family member 1B1 gene single nucleotide polymorphism, c.521 T > C. There is no epidemiologic data on this...
Source: BMC Medical Genomics - September 1, 2023 Category: Genetics & Stem Cells Authors: Mulata Haile Nega, Derbew Fikadu Berhe and Vera Ribeiro Tags: Research Source Type: research
Statins and immune-mediated necrotizing myopathy: Variability in the risk
CONCLUSION: Atorvastatin presents the highest risk of IMNM. Our data suggest that the occurrence of IMNM is a class effect.PMID:37625939 | DOI:10.1016/j.therap.2023.07.005
Source: Therapie - August 25, 2023 Category: Psychiatry & Psychology Authors: Thierry Trenque Jed Hadjoudj Agathe Trenque Federica Tralongo Salom é Martin Brahim Azzouz Source Type: research
Cell-free DNA as an potential marker of statin induced muscle injury
Background and Aims: The most commonly reported undesirable side effects of statin treatment are myalgia and myopathy. Short DNA fragments freely present in plasma (cfDNA) and potentially released from stressed and damaged muscle tissue could be important marker of such complications.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: J. Hubacek, P. Huckova, D. Dlouha, V. Adamkova, M. Vrablik Source Type: research
Impact of metformin on statin ‐associated myopathy risks in dyslipidemia patients
This study found that a comedication with metformin was associated with decreased myopathy risk in statin-treated dyslipidemia patients compared to statin-only users. Our findings suggest that metformin may provide protective effects on potential muscle toxicities induced by statin therapy.
Source: Pharmacology Research and Perspectives - July 8, 2023 Category: Drugs & Pharmacology Authors: Keunhyeong Bak,
Suhyeon Moon,
Minjung Ko,
Yeo Jin Choi,
Sooyoung Shin Tags: ORIGINAL ARTICLE Source Type: research
Development and validation of an eco-friendly HPLC –UV method for determination of atorvastatin and vitamin D3 in pure form and pharmaceutical formulation
Statin-associated muscle symptoms are considered as obvious adverse effects of prolonged statin therapy such as myopathy, myalgia, and rhabdomyolysis. These side effects are associated with vitamin D3 deficiency ...
Source: Chemistry Central Journal - June 20, 2023 Category: Chemistry Authors: Khaled Maged, Magda M. El-Henawee and Soad S. Abd El-Hay Tags: Research Source Type: research
Cardiovascular risk in myositis patients compared to the general population
CONCLUSION: Significantly higher prevalence of traditional risk factors and subclinical atherosclerosis was observed in IIM patients compared with HC.PMID:37279728 | DOI:10.1093/rheumatology/kead271
Source: Atherosclerosis - June 6, 2023 Category: Cardiology Authors: Sabina Oreska Hana Storkanova Jaroslav Kudlicka Vladimir Tuka Ondrej Mikes Zdislava Krupickova Martin Satny Eva Chytilova Jan Kvasnicka Maja Spiritovic Barbora Hermankova Petr Cesak Marian Rybar Karel Pavelka Ladislav Senolt Herman Mann Jiri Vencovsky Mic Source Type: research
Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management
Expert Rev Cardiovasc Ther. 2023 May 22. doi: 10.1080/14779072.2023.2215982. Online ahead of print.ABSTRACTINTRODUCTION: Statins are the cornerstone for atherosclerotic cardiovascular disease risk reduction with recognized efficacy in primary and secondary prevention. Despite this, they remain underutilized due to concerns regarding adverse effects. Statin-associated muscle symptoms (SAMS) are the most frequent cause of medication intolerance and discontinuation with a prevalence estimated at 10%, regardless of causality, with the consequence of increased risk of adverse cardiovascular outcomes.AREAS COVERED: This clinical...
Source: Expert Review of Cardiovascular Therapy - May 22, 2023 Category: Cardiology Authors: Iulia Iatan G B John Mancini Eunice Yeoh Robert A Hegele Source Type: research
Therapeutic challenges and cardiovascular risk in patients with HMGCR-associated immune-mediated necrotizing myopathy (HMGR-IMNM) secondary to statins
Eur J Intern Med. 2023 May 11:S0953-6205(23)00165-6. doi: 10.1016/j.ejim.2023.05.011. Online ahead of print.NO ABSTRACTPMID:37179139 | DOI:10.1016/j.ejim.2023.05.011
Source: European Journal of Internal Medicine - May 13, 2023 Category: Internal Medicine Authors: Jorge Álvarez-Troncoso Sergio Carrasco Molina Ángel Robles-Marhuenda Elena Mart ínez-Robles Juan Jos é Ríos-Blanco Source Type: research
Comment on & quot;Drug –Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data & quot;
Source: Drug Safety - April 15, 2023 Category: Drugs & Pharmacology Source Type: research
Author ’s Reply to Kuss and Rathmann’s Comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data”
Source: Drug Safety - April 15, 2023 Category: Drugs & Pharmacology Source Type: research
